Expanding roles of cell cycle checkpoint inhibitors in radiation oncology

被引:14
|
作者
Hauge, Sissel [1 ]
Eek Mariampillai, Adrian [1 ]
Rodland, Gro Elise [1 ]
Bay, Lilli T. E. [1 ]
Landsverk, Helga B. [1 ]
Syljuasen, Randi G. [1 ]
机构
[1] Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Res, Dept Radiat Biol, Ullernchausseen 70, N-0379 Oslo, Norway
关键词
Radiation; cell cycle checkpoints; DNA damage; repair; anti-tumor immune response; ATR inhibitor; CHK1; inhibitor; WEE1;
D O I
10.1080/09553002.2021.1913529
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Purpose Radiation-induced activation of cell cycle checkpoints have been of long-standing interest. The WEE1, CHK1 and ATR kinases are key factors in cell cycle checkpoint regulation and are essential for the S and G2 checkpoints. Here, we review the rationale for why inhibitors of WEE1, CHK1 and ATR could be beneficial in combination with radiation. Conclusions Combined treatment with radiation and inhibitors of these kinases results in checkpoint abrogation and subsequent mitotic catastrophe. This might selectively radiosensitize tumor cells, as they often lack the p53-dependent G1 checkpoint and therefore rely more on the G2 checkpoint to repair DNA damage. Further affecting the repair of radiation damage, inhibition of WEE1, CHK1 or ATR also specifically suppresses the homologous recombination repair pathway. Moreover, inhibition of these kinases can induce massive replication stress during S phase of the cell cycle, likely contributing to eliminate radioresistant S phase cells. Intriguingly, recent findings suggest that cell cycle checkpoint inhibitors in combination with radiation can also enhance anti-tumor immune effects. Altogether, the expanding knowledge about the functional roles of WEE1, CHK1 and ATR inhibitors support that they are promising candidates for use in combination with radiation treatment.
引用
收藏
页码:941 / 950
页数:10
相关论文
共 50 条
  • [1] The cell cycle checkpoint inhibitors in the treatment of leukemias
    A. Ghelli Luserna di Rora’
    I. Iacobucci
    G. Martinelli
    [J]. Journal of Hematology & Oncology, 10
  • [2] The cell cycle checkpoint inhibitors in the treatment of leukemias
    di Rora, A. Ghelli Luserna
    Iacobucci, I.
    Martinelli, G.
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2017, 10
  • [3] The landscape of checkpoint inhibitors in oncology
    Haslam, Alyson
    Kim, Myung Sun
    Elbaz, Josh
    Prasad, Vinay
    [J]. EUROPEAN JOURNAL OF CANCER, 2024, 209
  • [4] Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors
    Collins, I
    Garrett, MD
    [J]. CURRENT OPINION IN PHARMACOLOGY, 2005, 5 (04) : 366 - 373
  • [5] Immuno-oncology checkpoint inhibitors
    不详
    [J]. NATURE BIOTECHNOLOGY, 2022, 40 (07) : 1005 - 1005
  • [6] Checkpoint inhibitors: a cutting edge in oncology
    Jago, C.
    [J]. DRUGS OF TODAY, 2017, 53 (07) : 399 - 404
  • [7] Immune Checkpoint Inhibitors in Geriatric Oncology
    Sarah L. Cook
    Md Al Amin
    Shahla Bari
    Pradeep J. Poonnen
    Mustafa Khasraw
    Margaret O. Johnson
    [J]. Current Oncology Reports, 2024, 26 : 562 - 572
  • [8] Immune Checkpoint Inhibitors in Geriatric Oncology
    Cook, Sarah L.
    Al Amin, Md
    Bari, Shahla
    Poonnen, Pradeep J.
    Khasraw, Mustafa
    Johnson, Margaret O.
    [J]. CURRENT ONCOLOGY REPORTS, 2024, 26 (05) : 562 - 572
  • [9] The pathophysiology of the cell cycle in cancer and treatment strategies using various cell cycle checkpoint inhibitors
    Almalki, Sami G.
    [J]. PATHOLOGY RESEARCH AND PRACTICE, 2023, 251
  • [10] The expanding universe of checkpoint inhibitors for nasopharyngeal cancer
    Brigette B. Y. Ma
    Edwin P. Hui
    Anthony T. C. Chan
    [J]. Nature Medicine, 2021, 27 : 1512 - 1513